Bulk Pharmaceutical API Sources for ingrezza

Bulk Pharmaceutical API Sources for ingrezza

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS027321089
MedChemexpress MCE		HY-16771
AbaChemScene		CS-5908

INGREZZA Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This analysis identifies current and potential bulk active pharmaceutical ingredient (API) suppliers for INGREZZA (valbenazine) and examines the competitive landscape and patent status impacting API procurement. Valbenazine is indicated for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

What are the key API manufacturing requirements for valbenazine?

The synthesis of valbenazine involves multiple complex chemical steps. Key manufacturing requirements include expertise in stereoselective synthesis, handling of specific reagents, and stringent quality control measures to ensure API purity and consistency. The drug substance is valbenazine ditolterodine tartrate. The synthesis pathways generally involve:

• Chiral Resolution/Asymmetric Synthesis: Valbenazine is a chiral molecule, requiring either the resolution of a racemic mixture or an enantioselective synthesis to obtain the desired stereoisomer. This often involves specialized catalysts or chiral auxiliaries.
• Functional Group Transformations: The synthesis typically involves several steps of functional group manipulation, including esterification, amidation, and alkylation reactions.
• Salt Formation: The final API is formulated as a ditolterodine tartrate salt, requiring controlled crystallization and salt formation processes to achieve the desired polymorphic form and purity.
• Impurity Profiling and Control: Rigorous control over process-related impurities, residual solvents, and potential degradation products is essential to meet pharmaceutical standards. Analytical methods such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Mass Spectrometry (MS) are critical for characterization and quality assurance.

The United States Pharmacopeia (USP) monograph for valbenazine ditolterodine tartrate specifies limits for various impurities and dictates analytical testing procedures, which must be adhered to by API manufacturers.

Who are the current and potential bulk API suppliers for INGREZZA?

The primary bulk API supplier for INGREZZA is Neurocrine Biosciences, Inc., the originator and marketer of the drug. Neurocrine Biosciences manufactures the API internally or through contract manufacturing organizations (CMOs) under strict quality agreements. As of public disclosures, Neurocrine Biosciences has not formally identified specific third-party API manufacturers for commercial supply.

However, potential suppliers for valbenazine API would typically include:

• Contract Development and Manufacturing Organizations (CDMOs) with expertise in complex small molecule synthesis and chiral chemistry. Examples of companies with such capabilities include:
  • Lonza: Known for its broad range of pharmaceutical manufacturing services, including complex synthesis.
  • Catalent: Offers drug substance development and manufacturing solutions.
  • Samsung Biologics: Provides integrated CDMO services.
  • WuXi AppTec: A global CDMO with significant expertise in small molecule API development and manufacturing.
  • Piramal Pharma Solutions: Offers end-to-end API manufacturing services.
• Specialty API manufacturers that focus on stereoselective synthesis and high-potency APIs.

The selection of a CDMO for valbenazine API would depend on factors such as:

• Demonstrated capability in chiral synthesis.
• cGMP compliance and regulatory track record.
• Capacity to scale up production to meet commercial demand.
• Intellectual property considerations and freedom to operate.
• Cost-effectiveness.

A robust supply chain for INGREZZA API would likely involve multiple qualified suppliers to mitigate risks associated with single-sourcing.

What is the patent landscape for valbenazine and its API?

The patent landscape for valbenazine is critical for understanding potential generic competition and API sourcing opportunities. Key patents include:

• Composition of Matter Patents: These patents cover the valbenazine molecule itself.

  • U.S. Patent No. 8,168,666: Issued on May 1, 2012, and titled "Valine, L-, N-[(1S)-1-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-2-(1-methylethyl)propyl]-, 1-methyl ester, (2S)-2-hydroxybutanedioate (1:1)." This is a foundational patent covering valbenazine ditolterodine.
  • U.S. Patent No. 8,664,394: Issued on March 4, 2014, also covering valbenazine ditolterodine.
  • U.S. Patent No. 9,023,858: Issued on May 5, 2015, covering crystalline forms of valbenazine ditolterodine.

• Method of Use Patents: These patents cover the use of valbenazine for specific medical indications.

  • U.S. Patent No. 9,801,761: Issued on October 31, 2017, for the treatment of tardive dyskinesia.
  • U.S. Patent No. 10,039,659: Issued on August 7, 2018, for the treatment of chorea associated with Huntington's disease.

• Formulation Patents: Patents covering specific pharmaceutical formulations of valbenazine.

  • U.S. Patent No. 10,376,501: Issued on August 13, 2019, covering specific dosage forms.

• Process Patents: Patents covering specific synthetic routes or manufacturing processes for valbenazine API. These are often less publically detailed but are crucial for API manufacturers. Neurocrine Biosciences would hold patents related to its proprietary synthesis.

Patent Expirations:

The expiration dates of key patents determine the timeline for generic market entry.

• The primary composition of matter patents, such as U.S. Patent No. 8,168,666 and U.S. Patent No. 8,664,394, are set to expire around 2029-2031, depending on any granted patent term extensions (PTEs) or pediatric exclusivity.
• Method of use patents for tardive dyskinesia (e.g., U.S. Patent No. 9,801,761) would expire later, potentially extending market exclusivity for the innovator for specific indications.
• The crystalline form patents (e.g., U.S. Patent No. 9,023,858) can also impact generic formulation strategies.

Neurocrine Biosciences has engaged in patent litigation to defend its intellectual property, which can influence the actual market entry dates for generics. For instance, challenges to patent validity or inventorship can alter the expected expiration timelines.

What is the competitive landscape for valbenazine API?

The competitive landscape for valbenazine API is currently characterized by limited public disclosure of specific third-party manufacturers. However, the potential for generic entry after patent expiry creates a future competitive environment.

Current Landscape:

• Innovator Dominance: Neurocrine Biosciences controls the current supply of valbenazine API, either through internal manufacturing or undisclosed CMO partnerships. This ensures strict control over quality, supply chain integrity, and pricing.
• High Barrier to Entry: The complex synthesis of valbenazine, requiring specialized expertise in chiral chemistry and adherence to stringent cGMP standards, presents a significant barrier for new API manufacturers.
• Limited Public Information: Specific details about the manufacturing process and any external API suppliers are proprietary and not publicly disclosed by Neurocrine Biosciences.

Future Landscape (Post-Patent Expiry):

• Emergence of Generic API Manufacturers: Upon patent expiry, qualified API manufacturers will likely seek to produce generic valbenazine API. These would include established CDMOs and specialty API producers.
• Price Competition: The introduction of generic API suppliers will lead to increased price competition, driving down API costs.
• Quality and Regulatory Scrutiny: Generic API manufacturers will face intense scrutiny from regulatory agencies (e.g., FDA, EMA) to demonstrate bioequivalence and compliance with quality standards.
• Intellectual Property Challenges: Potential for litigation related to process patents or formulation patents may arise, impacting the speed of generic market entry.
• Supply Chain Diversification: Pharmaceutical companies seeking to market generic valbenazine will look to diversify their API supply chains, potentially engaging multiple API manufacturers to ensure supply security.

Key players in the generic API space that might emerge as suppliers include those with robust capabilities in complex chiral APIs. These companies would need to invest in process development and scale-up for valbenazine to be competitive.

What are the regulatory considerations for valbenazine API manufacturing?

The manufacturing of valbenazine API is subject to rigorous regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others.

Key regulatory considerations include:

• Current Good Manufacturing Practices (cGMP): API manufacturers must adhere to cGMP regulations as outlined in 21 CFR Parts 210 and 211 (U.S.) and EudraLex Volume 4 (Europe). This covers all aspects of production, from raw material sourcing and facility design to personnel training, process validation, and quality control.
• Drug Master File (DMF) Submission: API manufacturers typically submit a DMF to regulatory agencies. The DMF contains detailed information about the manufacturing process, controls, and quality of the API. Innovator companies reference these DMFs in their drug applications. For generic applications, the DMF is also critical.
• Process Validation: The entire manufacturing process for valbenazine API must be validated to ensure consistency and reproducibility. This includes demonstrating that the process consistently produces API meeting predefined specifications.
• Impurity Profiling and Control: Identification, qualification, and quantification of all process-related impurities, degradation products, and residual solvents are mandatory. Limits for impurities are established based on ICH guidelines (e.g., ICH Q3A, ICH Q3C).
• Analytical Method Validation: All analytical methods used for testing the API must be validated according to ICH Q2(R1) guidelines to ensure accuracy, precision, specificity, linearity, and robustness.
• Stability Studies: Comprehensive stability studies must be conducted under various temperature and humidity conditions to establish the retest period or shelf life of the API, as per ICH Q1A(R2).
• Change Control: Any changes to the manufacturing process, equipment, raw materials, or analytical methods must be carefully evaluated, documented, and, if necessary, reported to regulatory agencies.
• Site Inspections: Manufacturing facilities are subject to routine inspections by regulatory authorities to ensure ongoing compliance with cGMP.
• Supply Chain Security and Traceability: Robust systems for supply chain management and traceability are required to prevent counterfeiting and ensure the integrity of the API from manufacturer to finished drug product.

For any potential generic API manufacturer, obtaining regulatory approval for their valbenazine API requires a thorough understanding of these regulations and successful navigation of the DMF submission and review process.

What are the implications of valbenazine API sourcing for R&D and investment decisions?

The sourcing of valbenazine API has significant implications for both Research & Development (R&D) and investment decisions, particularly concerning generic development and supply chain strategy.

For R&D Decisions:

• Process Development for Generics: Generic R&D teams must develop a non-infringing, cost-effective, and scalable process for valbenazine API synthesis. This requires deep knowledge of existing patents and potential freedom-to-operate issues. Identifying potential API suppliers early in the R&D phase can influence process design and route selection.
• Analytical Method Development: Developing robust analytical methods to demonstrate equivalence to the innovator API and to control impurities is critical. This work is often done in parallel with process development.
• Formulation Development: The API's physical properties (e.g., particle size, polymorphic form), influenced by the API manufacturing process, directly impact formulation development. Collaboration between API suppliers and formulation scientists is essential.

For Investment Decisions:

• Generic Market Entry Timing: The expiration of key patents dictates the window for generic entry. Investors must assess the strength of remaining patents and the likelihood of successful patent challenges to predict market entry timelines and potential returns.
• API Supply Chain Risk Assessment: For companies developing generic INGREZZA, securing a reliable, high-quality API supplier is paramount. Investment decisions should consider the capabilities, regulatory track record, and financial stability of potential API manufacturers. Diversification of API sources is a key risk mitigation strategy.
• Cost of Goods Sold (COGS): The cost of the valbenazine API is a major component of the COGS for generic INGREZZA. The competitiveness of potential API suppliers will directly influence the profitability of generic products.
• Regulatory Hurdles: The cost and time associated with navigating regulatory approvals for generic API (DMF submission, site inspections) represent significant investment considerations. Companies with a strong regulatory affairs team and established relationships with API manufacturers may have a competitive advantage.
• Intellectual Property Landscape: Investing in generic development requires careful analysis of the patent landscape, including the risk of patent litigation. The outcome of such litigation can significantly impact investment value.

The proprietary nature of the innovator's API manufacturing process means that generic developers often need to invest heavily in independent process R&D and engage with CDMOs capable of developing novel, non-infringing synthetic routes.

Key Takeaways

• Valbenazine API manufacturing requires expertise in stereoselective synthesis and stringent cGMP compliance.
• Neurocrine Biosciences is the primary source of valbenazine API. Potential future suppliers include specialized CDMOs.
• Key composition of matter patents for valbenazine expire around 2029-2031, creating opportunities for generic API manufacturers.
• The current API competitive landscape is dominated by the innovator, but the future landscape will likely see price competition among generic suppliers.
• Regulatory considerations for valbenazine API include cGMP adherence, DMF submission, process validation, and impurity control.
• API sourcing decisions critically impact R&D timelines, formulation strategies, and investment returns for generic drug developers.

Frequently Asked Questions

1. When are the primary patents for INGREZZA expected to expire? The foundational composition of matter patents for valbenazine are projected to expire between 2029 and 2031, subject to patent term extensions and other regulatory exclusivities.

2. Are there any publicly listed third-party manufacturers for INGREZZA API? Neurocrine Biosciences, the innovator, has not publicly disclosed specific third-party manufacturers for INGREZZA API.

3. What specific chemical expertise is crucial for valbenazine API synthesis? Expertise in chiral resolution or asymmetric synthesis is critical, along with proficiency in handling specific reagents and performing complex functional group transformations, as well as salt formation.

4. How does the API manufacturing process influence generic formulation? The physical properties of the API, such as its polymorphic form and particle size distribution, which are determined by the manufacturing process, directly affect drug product stability, dissolution rates, and overall bioavailability, thus impacting formulation development.

5. What is the regulatory pathway for a new API manufacturer seeking to supply valbenazine API? A new API manufacturer must adhere to cGMP, validate their manufacturing process, establish impurity profiles, validate analytical methods, and submit a Drug Master File (DMF) to regulatory agencies for review.

---

Citations

[1] U.S. Patent No. 8,168,666. (2012, May 1). Valine, L-, N-[(1S)-1-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-2-(1-methylethyl)propyl]-, 1-methyl ester, (2S)-2-hydroxybutanedioate (1:1). United States Patent and Trademark Office. [2] U.S. Patent No. 8,664,394. (2014, March 4). Valine, L-, N-[(1S)-1-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-2-(1-methylethyl)propyl]-, 1-methyl ester, (2S)-2-hydroxybutanedioate (1:1). United States Patent and Trademark Office. [3] U.S. Patent No. 9,023,858. (2015, May 5). Crystalline Forms of Valbenazine Ditolterodine. United States Patent and Trademark Office. [4] U.S. Patent No. 9,801,761. (2017, October 31). Method for Treating Tardive Dyskinesia. United States Patent and Trademark Office. [5] U.S. Patent No. 10,039,659. (2018, August 7). Method for Treating Chorea Associated with Huntington's Disease. United States Patent and Trademark Office. [6] U.S. Patent No. 10,376,501. (2019, August 13). Dosage Forms. United States Patent and Trademark Office. [7] Food and Drug Administration. (n.d.). Current Good Manufacturing Practice, Packaging, and Labeling for Human Drugs in Commercial Distribution. 21 CFR Parts 210 and 211. [8] European Medicines Agency. (n.d.). EudraLex Volume 4 – GMP Guidelines. [9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2). [10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R8). [11] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2(R1). [12] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2).